Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18964945 | 0.78 | HTR3E (0.47) | GRM4NOTUM | |
| SCHEMBL10187271 | 0.75 | CES2 (0.41) | — | |
| SCHEMBL19523877 | 0.73 | AR (0.56) | AR | |
| SCHEMBL30977609 | 0.71 | KIF11 (0.53) | MPLARKMOKIF11PTPN7 | |
| SCHEMBL156681 | 0.71 | KIF11 (0.53) | MPLARKMOKIF11PTPN7 | |
| SCHEMBL19886480 | 0.71 | HTR2A (0.40) | MPLARKMOKIF11PTPN7 | |
| SCHEMBL7265211 | 0.70 | IDO1 (0.48) | MPLARKIF11SLC22A12 | |
| SCHEMBL31030963 | 0.70 | MPL (0.55) | MPLARKMOKIF11 | |
| SCHEMBL29775945 | 0.70 | IDO1 (0.48) | MPLARKIF11SLC22A12 | |
| SCHEMBL13390477 | 0.70 | RXRA (0.50) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | MPL 3471/4885AR 530/4885KMO 194/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | MPL 3471/4885AR 530/4885KMO 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.